Markers of Atherosclerosis in Overweight, Postmenopausal Women Following Daily Watermelon Consumption

July 8, 2019 updated by: Appalachian State University

Expression of Systemic Markers of Atherosclerosis in Free-living, Overweight, Postmenopausal Women Following Daily Watermelon Consumption for Six Weeks: A Randomized Controlled Trial

The primary purpose of this study is to determine the effectiveness of six weeks of watermelon puree supplementation, compared to control (no treatment), on blood antioxidant capacity, inflammation markers in the blood, biomarkers of metabolism in the blood, and cardiovascular disease markers in the blood, and biomarkers in the blood related to watermelon ingestion in overweight post-menopausal women. The secondary purpose is to compare body composition and body mass between the watermelon supplement group and the control group.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

ORIENTATION AND PRE-STUDY TESTING (1-2 hours):

  1. Come to the Lab in the morning in an overnight fasted state.
  2. Complete orientation to the study, and provide voluntary consent to join the study.
  3. Complete a medical health questionnaire to verify medical history and lifestyle habits, and provide a 3-day food record.
  4. Record symptoms on a questionnaire regarding how subjects have felt for the previous four weeks using a 12-point Likert scale. Symptoms relate to digestive health, hunger, energy, infection, pain, allergies, stress, mental focus, and overall wellbeing.
  5. All forms reviewed to determine eligibility to participate in this study.
  6. Subject height, body weight, and percent body fat measured.
  7. A blood sample taken by a trained phlebotomist; the sample not to exceed 40 mL. Blood tested for markers associated with inflammation and cardiovascular health, and nutritional compounds related to drinking watermelon puree.
  8. Subjects randomized to the Control or Watermelon group. If assigned to the Watermelon group subjects provided a six-week supply of watermelon puree.
  9. The morning of the study subjects consume the three bottles of watermelon puree (710 mL total, Watermelon group) each day thereafter for six weeks or maintain normal daily fluid intake (Control group).
  10. Six weeks after beginning the study subjects return to the Laboratory for the final measurements. Subjects to bring all beverage bottles.

6-WEEK LAB VISIT (1-2 hours):

  1. Participants come to the Lab in the morning in an overnight fasted state.
  2. Subject body weight, and percent body fat are measured.
  3. Subjects record symptoms on a questionnaire regarding how they have felt for the previous six weeks.
  4. A final blood sample (40 mL) taken by a trained phlebotomist.

BLOOD SAMPLE ANALYSES

  1. Blood borne cardiovascular disease markers: ADAM metallopeptidase with thrombospondin type 1 motif, 13 (ADAMTS13), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble P-selectin (sP-selectin), growth differentiation factor-15 (GDF-15), and soluble intercellular adhesion molecule-1 (sICAM-1) measured according to the manufacturer's specifications using the MAGPIX instrument and xPONENT analysis software (Luminex, Austin, TX).
  2. Fasting blood glucose, insulin, vitamin C, and high-sensitivity C-reactive (hs-CRP) protein were measured by LabCorp (Burlington, NC).
  3. Fasting plasma carotenoid concentrations measured commercially (Craft Technologies Inc., Wilson, NC).
  4. Fasting plasma amino acid concentration determined by high-performance liquid chromatography.

Study Type

Interventional

Enrollment (Actual)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • Boone, North Carolina, United States, 28608
        • Appalachian State University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 75 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Female
  • 50 to 75 years of age,
  • have not menstruated for at least 1 year (menopause),
  • have a BMI of ≥25 kg/m2,
  • nonsmoker with
  • no diagnosed history of chronic diseases including: coronary heart disease, stroke, cancer, type 1 or 2 diabetes mellitus, or rheumatoid arthritis;
  • may not regularly consume large quantities of L-citrulline/L-arginine rich foods (red meat, tuna fish, cheese, nuts),
  • may not regularly take L-citrulline/L-arginine supplements,
  • may not use anti-hypertension medications (including diuretic medications),
  • may not use exogenous ovarian hormones, or
  • may not use medications known to influence inflammation within the two weeks of the study period (specifically non-steroidal anti-inflammatory drugs; NSAIDS).

Exclusion Criteria:

  • Male,
  • younger than 50 or older than 75 years of age,
  • menstruated within the last year,
  • have a BMI of <25 kg/m2, smoker,
  • diagnosed history of chronic diseases including: coronary heart disease, stroke, cancer, type 1 or 2 diabetes mellitus, or rheumatoid arthritis;
  • regularly consume large quantities of L-citrulline/L-arginine rich foods (red meat, tuna fish, cheese, nuts),
  • regularly take L-citrulline/L-arginine supplements,
  • use anti-hypertension medications (including diuretic medications),
  • use exogenous ovarian hormones, or
  • use medications known to influence inflammation within the two weeks of the study period (specifically non-steroidal anti-inflammatory drugs; NSAIDS).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Control
No intervention
EXPERIMENTAL: Watermelon
Watermelon puree 710 mL per day for six weeks
Pureed whole (100%) watermelon

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in select plasma cardiovascular disease markers
Time Frame: Pre-study and study completion (6 weeks)
Plasma concentrations of ADAMTS13, sVCAM-1, sP-selectin, GDF-15, hs-CRP, and sICAM-1
Pre-study and study completion (6 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood glucose
Time Frame: Pre-study and study completion (6 weeks)
Fasting blood glucose
Pre-study and study completion (6 weeks)
Blood insulin
Time Frame: Pre-study and study completion (6 weeks)
Fasting blood insulin
Pre-study and study completion (6 weeks)
Blood carotenoids
Time Frame: Pre-study and study completion (6 weeks)
Fasting blood carotenoids
Pre-study and study completion (6 weeks)
Blood amino acids
Time Frame: Pre-study and study completion (6 weeks)
Fasting blood amino acids
Pre-study and study completion (6 weeks)
Body mass
Time Frame: Pre-study and study completion (6 weeks)
Body mass (kg)
Pre-study and study completion (6 weeks)
Body mass index
Time Frame: Pre-study and study completion (6 weeks)
Body mass index (kg/m2)
Pre-study and study completion (6 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: R. Andrew Shanely, Ph.D., Appalachian State University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 1, 2014

Primary Completion (ACTUAL)

July 1, 2014

Study Completion (ACTUAL)

July 1, 2014

Study Registration Dates

First Submitted

July 2, 2019

First Submitted That Met QC Criteria

July 8, 2019

First Posted (ACTUAL)

July 11, 2019

Study Record Updates

Last Update Posted (ACTUAL)

July 11, 2019

Last Update Submitted That Met QC Criteria

July 8, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Overweight and Obesity

Clinical Trials on Watermelon

3
Subscribe